Tier 4 — mechanistic

VIAging Deceleration Trial Using Metformin, Dasatinib, Rapamycin and Nutritional Supplements

Vitality in Aging Research Group study team
ClinicalTrials.gov trial registry record 2021

Bibliography

Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Sponsor: Vitality in Aging Research Group, Inc.
Competing interests
Registry record for a commercially adjacent multimodal anti-aging intervention; no peer-reviewed manuscript-level conflict statement is available.

Study snapshot

DesignPlanned Phase 1 open-label single-group multimodal intervention.
ModelAdults aged 65 years and older.
SampleNo completed enrolled cohort; trial was withdrawn.
InterventionSequential regimen including metformin, dasatinib, bio-quercetin, bio-fisetin 44.5 mg for two consecutive days every three months, daily glucosamine, nicotinamide riboside and trans-resveratrol, plus weekly rapamycin.
DurationPlanned approximately one year of multimodal treatment with longer safety follow-up.
EndpointsTreatment-emergent adverse events; Visceral adipose tissue; Blood pressure; MMP-9; Insulin resistance; DNA methylation / GrimAge

What the study showed, in plain terms

VIAging was designed as a single-group Phase 1 program combining multiple prescription drugs and supplements, including 44.5 mg of bio-fisetin on two consecutive days every three months.

The study was withdrawn and did not generate an efficacy dataset. Even if completed, the many simultaneous interventions would have made it impossible to attribute changes specifically to fisetin.

Key findings

  • Bio-fisetin 44.5 mg was one component of a much larger drug-and-supplement regimen.
  • The trial was open-label and had no control group.
  • The study was withdrawn before producing outcome evidence.

What this study can and cannot tell us

  • Withdrawn study with no efficacy results.
  • Multiple drugs and supplements prevent fisetin-specific attribution.
  • Open-label single-group design would have been highly vulnerable to confounding even if completed.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology